Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 2 CLINICAL STUDY OF POMALIDOMIDE (CC-4047) MONOTHERAPY FOR CHILDREN AND YOUNG ADULTS WITH RECURRENT OR PROGRESSIVE PRIMARY BRAIN TUMORS

Trial Profile

A PHASE 2 CLINICAL STUDY OF POMALIDOMIDE (CC-4047) MONOTHERAPY FOR CHILDREN AND YOUNG ADULTS WITH RECURRENT OR PROGRESSIVE PRIMARY BRAIN TUMORS

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Dec 2018

At a glance

  • Drugs Pomalidomide (Primary)
  • Indications Brain cancer; Ependymoma; Glioma; Medulloblastoma
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 02 Dec 2018 Planned End Date changed from 27 Nov 2018 to 18 Mar 2023.
    • 02 Dec 2018 Planned primary completion date changed from 13 Aug 2018 to 11 Mar 2019.
    • 02 Aug 2018 Planned End Date changed from 13 Aug 2018 to 27 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top